Expression And Significance Of Clusterin,p53,bcl-2 And Fasl In Prostate Cancer

Objective:To investigate the expression and significance of an inhibitor of apoptosis, Clusterin,in prostate cancer, and its relationship with the expression of p53,bcl-2 and FasL. Methods:The expression of Clusterin ,p53,bcl-2 and FasL in sample of 10 normal prostate ,15 BPH and 49 prostate cancer were examined by immunohistochemical stain. Results : The rate of positive or weak positive for normal prostate ,BPH and prostate cancer was 10%(1/10),66.6%(10/15)and 91.8%(45/49) respectively. The expression level of Clusterin in prostate cancer was much higher than in normal prostate ( P<0.005 ) ,BPH(P<0.005),and it was related positively with clinical stage (P<0.001)and pathological grade(P<0.001)of prostate cancer. The expression level of Clusterin in prostate cancer was related positively with p53(P<0.001), bcl-2 (P<0.05)and FasL expression (P<0.05). The expression level of Clusterin in prostate cancer was related positively with PSA ( P <0.01).However, the expression of Clusterin in prostate cancer showed negative correlation with the survival time of these patients(P<0.05). Conclusion: Clusterin,alone or in cooperarion with p53,bcl-2 and FasL,may play an important role in the onset and progression of prostate cancer by the antiapoptosis pathway. Clusterin could be a new diagnostic/therapeutic target in prostate cancer, especial hormonal independent cancer.